Satya Nadella and Michel Vounatsos: Two CEO Gambles

On paper, Satya Nadella and Michel Vounatsos have almost nothing in common. One is an Indian-born engineer who runs the most valuable software company on earth. The other is a French-born, Moroccan-raised pharmaceutical executive who ran a Cambridge biotech firm. They have never worked together, never sat on the same board, and move in entirely different industries.

But look closer and the two careers rhyme in a way that is hard to ignore. Both men were born outside the United States and rose to the top of iconic American companies in the same era. Both inherited legacy giants that the world had started to count out. And both staked everything — their reputations, their companies’ futures — on a single generation-defining bet. Nadella bet Microsoft on the cloud and then on artificial intelligence. Vounatsos bet Biogen on curing Alzheimer’s disease. One of those bets became the business story of the decade. The other became a cautionary tale.

This is their story, side by side: two immigrant chief executives, two moonshots, two wildly different endings — plus an honest accounting of what each man is actually worth, with every number tied to a published source.

Quick Bio: Satya Nadella

Quick Bio: Michel Vounatsos

The Hyderabad Engineer Who Reinvented Microsoft

Satya Nadella was born on August 19, 1967, in Hyderabad, India, into a household that prized both public service and scholarship. His father, Bukkapuram Nadella Yugandhar, was a senior Indian Administrative Service officer and economist; his mother, Prabhavati, was a professor of Sanskrit. Young Satya attended the Hyderabad Public School in Begumpet, failed his attempt at the fiercely competitive IIT entrance exam, and instead earned a bachelor’s degree in electrical engineering from the Manipal Institute of Technology in 1988.

America came next: a master’s in computer science from the University of Wisconsin-Milwaukee in 1990, a first job at Sun Microsystems, and then, in 1992, a move to a Seattle-area software company called Microsoft. He would spend more than two decades there in near-anonymity, running the server and tools businesses, and later the Cloud and Enterprise group — the unglamorous engine room that would become Azure. Along the way he earned an MBA from the University of Chicago Booth School of Business in 1997, studying while working full time.

On February 4, 2014, the board handed him the job nobody envied. Microsoft was profitable but stagnating, mocked as a relic of the PC era, its best days supposedly behind it. Nadella became only the third CEO in the company’s history, after Bill Gates and Steve Ballmer. What followed is now business-school legend. He declared a cloud-first, mobile-first strategy, opened Microsoft to Linux and open source, released Office for the iPad, bought Mojang — the maker of Minecraft — and, most consequentially, poured billions into OpenAI and its ChatGPT technology, a move one senior executive called Microsoft’s “Windows 95 moment.”

The numbers tell the rest. Microsoft shares have returned more than 1,000 percent since his first day as CEO. The company became the second-largest in the world and the frontrunner in the race to capitalize on artificial intelligence. In 2019 the Financial Times named him Person of the Year, declaring that “Microsoft was at risk of technological irrelevance but the chief executive has presided over an era of stunning wealth creation.” He has since added the chairman’s title, written a bestselling memoir, “Hit Refresh” — donating all proceeds to Microsoft Philanthropies — and become that rarest of things: a tech CEO whom politicians and regulators do not revile.

The Six-Language Marathoner Who Ran Biogen

Michel Vounatsos arrived at Biogen with a resume that read like a passport. A French national of Greek extraction, born and raised in Morocco, he spoke six languages and had run marathons on three continents. He had spent two decades at Merck & Co., leading the company’s primary care business globally, running MSD’s operations in China, and holding commercial leadership posts across Europe. Before Merck, he worked at Ciba-Geigy, the Swiss drug giant that later became part of Novartis. His education was equally cross-continental: an MBA from the HEC School of Management in Paris and a medical certificate from the Universite Victor Segalen in Bordeaux.

When the Boston Globe profiled him as Biogen’s new boss in January 2017, the pitch was his global perspective. Biogen was Massachusetts’ largest biotech, dominant in multiple sclerosis drugs but concentrated in North America and Europe, with no operations in China, South Korea, or Taiwan. Vounatsos promised to take the company global and to chase the industry’s holy grail: a breakthrough treatment for Alzheimer’s disease.

For a while, the bet looked inspired. Biogen’s Alzheimer’s drug Aduhelm won accelerated FDA approval in June 2021 — the first new Alzheimer’s treatment in nearly two decades. Then the story curdled with astonishing speed. The FDA’s own external advisory committee had rejected the drug; the agency approved it anyway, and several committee members resigned in protest. Harvard professor Aaron Kesselheim called it “probably the worst drug approval decision in recent U.S. history.” Doctors hesitated to prescribe it, insurers refused to pay for it, and in April 2022 the U.S. Centers for Medicare and Medicaid Services sharply limited coverage. Biogen chopped the price in half to $28,200 a year. It did not matter.

On May 3, 2022, Biogen announced that Vounatsos would step down as CEO. He called his tenure “a good term” and the transition “a natural event,” but nobody in the industry was fooled: the Aduhelm disaster had ended his run. He stayed on until a successor was found, departing in November 2022. The company pivoted to a different Alzheimer’s drug, lecanemab, developed with partner Eisai, eliminated the Aduhelm sales team, and announced plans to cut $1 billion in annual spending.

Two Moonshots, Two Very Different Outcomes

This is the heart of the comparison, and it is why these two names belong in the same article. Nadella and Vounatsos each took over an iconic company at an inflection point and each made a bet-the-company wager on the future. Nadella’s wager was that computing would move to the cloud and then to AI, and that Microsoft — the company of Windows and Office — could lead both revolutions. Vounatsos’s wager was that Biogen could do what no drug company had ever done: slow Alzheimer’s disease.

Both bets required the same leadership muscle — convincing skeptical boards, investors, and employees to pour billions into an uncertain future. Both men were outsiders in a sense: Nadella an engineer in a company run by salesmen, Vounatsos a commercial executive in a company run by scientists. And both bets were, at the moment they were made, genuinely courageous.

The difference was execution and luck. Nadella’s cloud pivot compounded year after year; the OpenAI investment turned Microsoft into the AI era’s defining incumbent. Vounatsos’s Alzheimer’s bet ran into the hardest problem in medicine — a disease that has humbled every drugmaker that has touched it — compounded by a regulatory and commercial fiasco that destroyed trust in the product. One moonshot made its CEO a billionaire and a legend. The other cost its CEO his job. There is no moral to that beyond the oldest one in business: the size of the bet does not determine the outcome.

Counting the Fortunes

Here the two men diverge as sharply as their careers did. Nadella belongs to one of the most exclusive clubs in capitalism: the “employee billionaires” — executives who reached ten figures without founding the company. Forbes estimated his net worth at $1.1 billion as of October 2025; other wealth trackers put the figure at $1.3 to $1.4 billion in early 2026. Bloomberg calculated that his total payouts from Microsoft — equity grants, salary, bonuses, and dividends parsed from regulatory filings — had topped $1 billion, powered by Microsoft stock’s 1,000-percent-plus run.

But this is one of those rare cases where the subject disputes the number. A Microsoft spokesperson, Frank Shaw, told Bloomberg by email that Nadella “does not have net worth of a billion dollars or more,” declining to elaborate. The gap between the estimates and the denial is a reminder of how much guesswork goes into these figures: nobody outside Nadella’s accountants knows what he has spent, gifted — filings show he has given away shares worth $20 million over the years — or invested privately. The honest range, sourced and attributed: roughly $1.1 to $1.4 billion according to published trackers, with Microsoft itself pushing back.

Vounatsos’s fortune is far more modest and far less disputed. MarketRealist, citing Wallmine, estimated his net worth at over $32 million when he stepped down in 2022. The math is straightforward: in 2020, his last full peak year, he received nearly $18.4 million in total compensation — about $1.5 million in salary, more than $2.5 million in bonuses, and $13.8 million in Biogen stock. Five years of that kind of pay, plus two decades at Merck before it, builds a very comfortable fortune. It does not build a billion.

The contrast is the point. Both men ran major public companies. Both were paid like it. But Nadella’s wealth compounded with Microsoft’s stock; Vounatsos’s peaked with Biogen’s. In the end, a CEO’s fortune is a derivative of the company’s trajectory — and these two trajectories could not have diverged more.

Where They Are Now

Nadella remains firmly in the seat, now as both chairman and CEO, steering Microsoft through the AI era he helped create. His $96.5 million pay package for fiscal 2025 — the biggest of his tenure, nearly 90 percent of it in stock awards on a $2.5 million base salary — reflects a board that believes the AI bet still has room to run. He lives in Bellevue, Washington, with his wife Anupama; they are part-owners of the Seattle Sounders FC soccer club. He serves on the boards of the Fred Hutchinson Cancer Research Center and the University of Chicago, and remains, by all accounts, the cricket-loving poetry reader he always was.

Vounatsos has rebuilt his career the way ousted CEOs do: through boardrooms. He sits on the boards of Revvity, the life-sciences and diagnostics company, and Zai Lab, the global biopharma firm, and he has joined the board of Quris-AI, a startup working at the intersection of AI and biology with a “patient-on-a-chip” drug-discovery platform — a telling choice for a man whose career was defined by the collision of biology and big bets. He also serves on the MIT Presidential CEO Advisory Board. The Aduhelm chapter is closed; the next one is about advising rather than commanding.

Frequently Asked Questions

What is Satya Nadella’s net worth?

Published estimates vary. Forbes estimated it at $1.1 billion as of October 2025, while other trackers estimated $1.3 to $1.4 billion in early 2026. Microsoft itself disputes the billion-dollar figure — a spokesperson said Nadella “does not have net worth of a billion dollars or more.” His wealth comes almost entirely from Microsoft stock and compensation.

What is Michel Vounatsos’s net worth?

MarketRealist, citing Wallmine, estimated it at over $32 million in 2022. His peak compensation came in 2020, when he received nearly $18.4 million in total pay from Biogen, including about $1.5 million in salary and $13.8 million in stock.

Why did Michel Vounatsos leave Biogen?

He announced his departure on May 3, 2022, amid the collapse of Aduhelm, Biogen’s Alzheimer’s drug. After a controversial FDA approval, doctors’ reluctance to prescribe it, insurers’ refusal to cover it, and a Medicare decision sharply limiting coverage, the drug flopped commercially and Vounatsos stepped down. He remained until a successor was found in November 2022.

Are Satya Nadella and Michel Vounatsos connected professionally?

No. They have never worked together or shared a board. The pairing is a comparison: both are immigrant-born CEOs who took over iconic American companies in the same era and staked their legacies on generation-defining bets — with opposite outcomes.

Is Satya Nadella still CEO of Microsoft?

Yes. He has been CEO since February 2014 and also holds the chairman title. His fiscal 2025 compensation of $96.5 million was the largest of his tenure.

What is Michel Vounatsos doing now?

He serves on the boards of Revvity, Inc. and Zai Lab, and has joined the board of Quris-AI, an AI-driven drug-discovery company. He is also on the MIT Presidential CEO Advisory Board.

The Bottom Line

There is a version of this story in which Michel Vounatsos is the hero: the worldly executive who cured Alzheimer’s and became a legend of medicine. There is a version in which Satya Nadella is the footnote: the quiet engineer who couldn’t save a dying software giant. We got the opposite versions, and the difference came down to the bets they placed and the industries they placed them in.

What endures about both men has little to do with the outcomes. Nadella proved that a legacy company can reinvent itself completely — that culture, as he likes to say, can learn. Vounatsos proved something quieter: that swinging at the hardest problem in medicine is worth doing even when you miss, and that a career can survive the miss. As Beverly Magazine often finds in its profiles of business leaders, the most instructive careers are not the flawless ones. They are the ones where the stakes were real, the outcome was uncertain, and the leader swung anyway.